Table 1.
Baseline characteristics of included trials
| Study | Phase | Total | Treatment regimens | Median age (years) | Median PFS (months) | Median duration of carfilzomib |
|---|---|---|---|---|---|---|
| Siegel et al27 | II | 266 | Carfilzomib 20/27 mg/m2 | 63 | 15.6 | 3.0 |
| Vij et al26 | II | 164 | Carfilzomib 20 mg/m2 | 65 | NR | 7.0 |
| Jagannath et al28 | II | 46 | Carfilzomib 20 mg/m2 | 63.5 | 3.5 | NR |
| Badros et al25 | II | 50 | Carfilzomib 20 mg/m2 followed by 27 mg/m2 | 64 | NR | NR |
| Korde et al24 | II | 45 | Carfilzomib 20/36 mg/m2+lenalidomide+dexamethasone | 60 | NR | 16 |
| Dimopoulos et al22 | III | 929 | Carfilzomib 20 mg/m2+dexamethasone | 65 | 18.7 | 9.3 |
| Bortezomib+dexamethasone | 65 | 9.4 | 6.3 | |||
| Hajek et al21 | III | 315 | Carfilzomib 20 mg/m2 | 63 | 3.7 | 3.8 |
| Low-dose corticosteroids | 66 | 3.3 | 2.5 | |||
| Stewart et al23 | III | 792 | Carfilzomib 20 mg/m2+lenalidomide+dexamethasone | 64 | 26.3 | 20.5 |
| Lenalidomide+dexamethasone | 65 | 17.6 | 13.3 |
Abbreviations: PFS, progression-free survival; NR, not reported.